Why Johnson & Johnson Stock Dropped Today

Johnson & Johnson shares fell 6.8% by 12:30 p.m. ET Tuesday despite Q3 adjusted EPS of $2.59 versus $2.53 expected and a slight sales beat. Sales grew 5.9%, but GAAP EPS fell 96% year over year to $0.09; J&J attributed the decline to a one-time charge, while free cash flow rose more than 6% to $15.1 billion. Management raised 2026 guidance to 7.4% sales growth, or $101.2 billion, and adjusted EPS of $11.10, though the article argues the valuation—over 22 times adjusted earnings and about 29 times free cash flow—is too high for roughly 7% growth.

Analysis

The selloff looks less like a verdict on one quarter’s GAAP charge and more like a credibility/valuation test: investors are discounting the quality of earnings when adjusted profit declines despite sales growth, while litigation and deal-related adjustments recur. The GAAP plunge alone is not a clean read-through to operating deterioration; the key check is whether the cited items consume cash or remain accounting charges, and whether free-cash-flow improvement persists after working-capital effects.

Near term, guidance is supportive, but does not by itself resolve the multiple risk. Over 1–3 months, watch the next filing for cash paid or reserved for talc matters, reconciliation of adjusted-to-GAAP earnings, and segment-level growth/margins. Over 6–18 months, the thesis turns on whether organic growth and cash conversion can sustain the premium without leaning on exclusions; verify product-level growth and exposure to upcoming loss of exclusivity before underwriting that trajectory.

Contrarian read: the sharp decline may over-penalize a largely discrete charge, especially with higher full-year guidance and cash generation. But the more consequential concern is that investors may be treating adjustments as temporary while the underlying earnings trend is weaker. No basis here to call the shares outright cheap or to project a target price.

Key Decisions for Investors

• Avoid chasing the post-earnings decline or initiating an outright short solely on the GAAP EPS figure. Reassess after the filing clarifies the cash and recurring-earnings impact of the talc and transaction charges.
• For existing JNJ exposure, consider trimming to a benchmark-weight position if the investment case depends on premium-multiple growth; retain exposure only while guidance and free-cash-flow conversion remain intact.
• Watch for a downside catalyst over the next 1–3 months: evidence that legal-related cash costs are larger or more persistent than implied, a weaker organic-growth/margin mix, or a reduction in full-year guidance. Those would strengthen a bearish thesis; clean cash reconciliation and continued guidance delivery would falsify it.
• Do not put on a directional options trade yet: verify the adjusted-to-GAAP bridge, cash paid versus accrued for litigation, and segment-level organic growth first. If those data confirm deterioration while the valuation remains elevated, consider a defined-risk JNJ put spread rather than an unbounded short.